# Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct02782026` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02782026](<https://clinicaltrials.gov/study/NCT02782026>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02782026

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.

## Technical summary

Registry record NCT02782026. Non-randomized; no masking; primary purpose diagnostic. Start 2016-03-04 (actual); primary completion 2018-08-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 273 participants (enrolled count; ClinicalTrials.gov record NCT02782026, source copy `cardio:ctgov-nct02782026-2021-05-04`, retrieved 2026-10-31)
- Started: 2016-03-04 (actual) (ClinicalTrials.gov record NCT02782026, source copy `cardio:ctgov-nct02782026-2021-05-04`, retrieved 2026-10-31)
- Primary completion: 2018-08-28 (actual) (ClinicalTrials.gov record NCT02782026, source copy `cardio:ctgov-nct02782026-2021-05-04`, retrieved 2026-10-31)
- Completion: 2018-09-04 (actual) (ClinicalTrials.gov record NCT02782026, source copy `cardio:ctgov-nct02782026-2021-05-04`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT02782026, source copy `cardio:ctgov-nct02782026-2021-05-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02782026-2021-05-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension
- Acronym: SNOOPY2
- Condition: Pulmonary Hypertension
- Intervention (Device): Exhaled Breath Olfactory Signature (Artificial Nose)
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Technion, Israel Institute of Technology
- Collaborator class: OTHER
- Collaborator: Bayer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)

## Provenance

Content hash: cc399ce38bf3ef2bcc9c4db5e02746efb4b29a5f4dc59546b76081365b3059a0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
